Published March 31, 2020
| Version v1
Dataset
Open
Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches
Creators
- 1. Istituto Nazionale Tumori - IRCCS - "Fond G. Pascale", Naples, Italy
Description
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, there is a single drug approved as first-line systemic therapy in advanced unresectable HCC, providing a very limited survival benefit. In earlier stages, 5-year survival rates after surgical and loco-regional therapies are extremely variable depending on the stage of disease.
Nevertheless, HCC is considered an immunogenic tumor arising in chronically inflamed livers.
In such a scenario, immunotherapy strategies for HCC, in particular combinations including cancer vaccines, may represent a key therapeutic tool to improve clinical outcome in HCC patients. However, a lot of improvement is needed given the disappointing results obtained so far.
Files
Files
(94.5 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:d70e72b894a82f924b670b16a82afc0f
|
94.5 kB | Download |
Additional details
Related works
- Is cited by
- Journal article: 10.1016/j.canlet.2019.12.029 (DOI)
Funding
Subjects
- PUBLICATION
- 10.1016/j.canlet.2019.12.029